ERFE and sarcopenia: Myonectin mitigates skeletal muscle dysfunction via an AMPK/PGC 1α-dependent mechanism. In aging sarcopenia, the degradation of myonectin results in heightened mitochondrial dysfunction within denervated skeletal muscle, exacerbating muscle atrophy.